Sarepta Therapeutics annual total assets
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sarepta Therapeutics Total Assets Growth & History (SRPT)
Sarepta Therapeutics's total assets was $3.35B for fiscal 2025.
View full Sarepta Therapeutics company overviewSarepta Therapeutics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.35B | −$613.5M | −15.48% |
| 2024 | 2024-12-31 | $3.96B | $698.6M | +21.40% |
| 2023 | 2023-12-31 | $3.26B | $136.2M | +4.35% |
| 2022 | 2022-12-31 | $3.13B | −$19.6M | −0.62% |
| 2021 | 2021-12-31 | $3.15B | $163.3M | +5.47% |
| 2020 | 2020-12-31 | $2.98B | $1.16B | +63.74% |
| 2019 | 2019-12-31 | $1.82B | $180.7M | +11.01% |
| 2018 | 2018-12-31 | $1.64B | $334.1M | +25.54% |
| 2017 | 2017-12-31 | $1.31B | $883.9M | +208.41% |
| 2016 | 2016-12-31 | $424.1M | $150.3M | +54.91% |
| 2015 | 2015-12-31 | $273.8M | −$21.3M | −7.20% |
| 2014 | 2014-12-31 | $295.0M | $3.5M | +1.19% |
| 2013 | 2013-12-31 | $291.6M | $86.6M | +42.23% |
| 2012 | 2012-12-31 | $205.0M | $150.6M | +277.05% |
| 2011 | 2011-12-31 | $54.4M | $8.4M | +18.25% |
| 2010 | 2010-12-31 | $46.0M | — | — |
Sarepta Therapeutics quarterly total assets
Q4.10
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.19B | −$491.3M | −13.35% |
| Q1 2026 | 2026-03-31 | $3.18B | −$286.5M | −8.27% |
| Q4 2025 | 2025-12-31 | $3.35B | −$613.5M | −15.48% |
| Q3 2025 | 2025-09-30 | $3.49B | −$106.5M | −2.96% |
| Q2 2025 | 2025-06-30 | $3.68B | $255.6M | +7.46% |
| Q1 2025 | 2025-03-31 | $3.47B | $241.0M | +7.47% |
| Q4 2024 | 2024-12-31 | $3.96B | $698.6M | +21.40% |
| Q3 2024 | 2024-09-30 | $3.60B | $490.2M | +15.76% |
| Q2 2024 | 2024-06-30 | $3.42B | $298.4M | +9.55% |
| Q1 2024 | 2024-03-31 | $3.22B | $164.6M | +5.38% |
| Q4 2023 | 2023-12-31 | $3.26B | $136.2M | +4.35% |
| Q3 2023 | 2023-09-30 | $3.11B | −$46.4M | −1.47% |
| Q2 2023 | 2023-06-30 | $3.13B | $129.0M | +4.31% |
| Q1 2023 | 2023-03-31 | $3.06B | $3.6M | +0.12% |
| Q4 2022 | 2022-12-31 | $3.13B | −$19.6M | −0.62% |
| Q3 2022 | 2022-09-30 | $3.16B | $493.9M | +18.55% |
| Q2 2022 | 2022-06-30 | $3.00B | $237.8M | +8.62% |
| Q1 2022 | 2022-03-31 | $3.06B | $290.9M | +10.52% |
| Q4 2021 | 2021-12-31 | $3.15B | $163.3M | +5.47% |
| Q3 2021 | 2021-09-30 | $2.66B | −$118.4M | −4.26% |
| Q2 2021 | 2021-06-30 | $2.76B | −$124.0M | −4.30% |
| Q1 2021 | 2021-03-31 | $2.77B | −$182.2M | −6.18% |
| Q4 2020 | 2020-12-31 | $2.98B | $1.16B | +63.74% |
| Q3 2020 | 2020-09-30 | $2.78B | $1.08B | +63.33% |
| Q2 2020 | 2020-06-30 | $2.88B | $1.14B | +64.96% |
| Q1 2020 | 2020-03-31 | $2.95B | $983.5M | +50.08% |
| Q4 2019 | 2019-12-31 | $1.82B | $180.7M | +11.01% |
| Q3 2019 | 2019-09-30 | $1.70B | $519.6M | +43.92% |
| Q2 2019 | 2019-06-30 | $1.75B | $500.6M | +40.14% |
| Q1 2019 | 2019-03-31 | $1.96B | $663.6M | +51.04% |
| Q4 2018 | 2018-12-31 | $1.64B | $334.1M | +25.54% |
| Q3 2018 | 2018-09-30 | $1.18B | $382.6M | +47.81% |
| Q2 2018 | 2018-06-30 | $1.25B | $797.0M | +177.06% |
| Q1 2018 | 2018-03-31 | $1.30B | $788.8M | +154.19% |
| Q4 2017 | 2017-12-31 | $1.31B | $883.9M | +208.41% |
| Q3 2017 | 2017-09-30 | $800.3M | $313.0M | +64.22% |
| Q2 2017 | 2017-06-30 | $450.1M | $246.1M | +120.58% |
| Q1 2017 | 2017-03-31 | $511.5M | $298.2M | +139.75% |
| Q4 2016 | 2016-12-31 | $424.1M | $150.3M | +54.91% |
| Q3 2016 | 2016-09-30 | $487.3M | $302.6M | +163.77% |
| Q2 2016 | 2016-06-30 | $204.1M | −$27.6M | −11.93% |
| Q1 2016 | 2016-03-31 | $213.4M | −$29.3M | −12.09% |
| Q4 2015 | 2015-12-31 | $273.8M | −$21.3M | −7.20% |
| Q3 2015 | 2015-09-30 | $184.8M | −$134.3M | −42.09% |
| Q2 2015 | 2015-06-30 | $231.7M | −$105.6M | −31.31% |
| Q1 2015 | 2015-03-31 | $242.7M | −$32.7M | −11.87% |
| Q4 2014 | 2014-12-31 | $295.0M | $3.5M | +1.19% |
| Q3 2014 | 2014-09-30 | $319.1M | $14.6M | +4.79% |
| Q2 2014 | 2014-06-30 | $337.3M | $153.7M | +83.69% |
| Q1 2014 | 2014-03-31 | $275.4M | $82.0M | +42.44% |
| Q4 2013 | 2013-12-31 | $291.6M | $86.6M | +42.23% |
| Q3 2013 | 2013-09-30 | $304.5M | $251.4M | +473.60% |
| Q2 2013 | 2013-06-30 | $183.6M | $141.5M | +336.17% |
| Q1 2013 | 2013-03-31 | $193.3M | $146.7M | +314.47% |
| Q4 2012 | 2012-12-31 | $205.0M | $150.6M | +277.05% |
| Q3 2012 | 2012-09-30 | $53.1M | −$8.0M | −13.10% |
| Q2 2012 | 2012-06-30 | $42.1M | −$32.8M | −43.82% |
| Q1 2012 | 2012-03-31 | $46.6M | — | — |
| Q4 2011 | 2011-12-31 | $54.4M | $8.4M | +18.25% |
| Q3 2011 | 2011-09-30 | $61.1M | — | — |
| Q2 2011 | 2011-06-30 | $74.9M | — | — |
| Q4 2010 | 2010-12-31 | $46.0M | — | — |
Sarepta Therapeutics total assets trends
Over the last five fiscal years, Sarepta Therapeutics's total assets increased from $2.98B to $3.35B, a change of $365.0M. The latest reported quarter, Q2 2026, shows $3.19B.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sarepta Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...